These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 3030864)

  • 41. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
    White CJ; Stinson D; Staehle B; Cho I; Matthews H; Ngai A; Keller P; Eiden J; Kuter B
    Clin Infect Dis; 1997 May; 24(5):925-31. PubMed ID: 9142794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
    Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
    Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned?
    Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF
    Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462
    [No Abstract]   [Full Text] [Related]  

  • 47. [Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox].
    Buxbaum S; Doerr HW; Allwinn R
    Dtsch Med Wochenschr; 2001 Nov; 126(46):1289-93. PubMed ID: 11709730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine.
    Berger R; Just M
    J Biol Stand; 1988 Oct; 16(4):275-9. PubMed ID: 2848843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.
    Ramet J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S49-55. PubMed ID: 18162247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
    Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
    Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q
    Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.